News and Resources

Dexpramipexole Kv 7 Company News
01.14.21

Knopp Biosciences Announces Positive Top-Line Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma

Discover this News
01.04.21

Dexpramipexole Targets Eosinophilic Inflammation

Discover this News
11.11.20

Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

Discover this News
10.08.20

Knopp Biosciences NIH-funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Discover this News
09.16.20

Knopp Biosciences Completes Enrollment in Phase 2 Trial of Oral Dexpramipexole in Eosinophilic Asthma

Discover this News
08.17.20

Knopp Biosciences to Present at Oppenheimer’s Private Life Sciences Company Call Series Aug. 18

Discover this News
07.15.20

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Discover this News
07.08.20

Knopp Biosciences Appoints Stephen E. Butts to Board of Managers

Discover this News
12.12.19

Knopp Biosciences Company Overview

Discover this News
1 2 3